Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical says

Reuters2026/08/11 23:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sumitomo Chemical flagged a statement from subsidiary Sumitomo Pharma disputing a Gotham City Research report published Aug. 7, 2026.
Sumitomo Pharma rejected the report’s assertions, noting the publisher disclosed short positions that could profit from a share-price decline.
Sumitomo Pharma defended AMCHEPRY, citing reliability of regulatory submissions, conditional time-limited approval, ongoing Phase 4 study toward full approval.
The unit also referenced an Aug. 3, 2026 report on financial reporting, warning of possible legal action over misleading information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Chemical Co. Ltd. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical says

You may also like

Crypto prices